Global Relapsed Acute Myeloid Leukemia Drug Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Relapsed Acute Myeloid Leukemia Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Product
  • 1.4.2 aNK Program
  • 1.4.3 AT-9283
  • 1.4.4 BI-836858
  • 1.4.5 binimetinib
  • 1.4.6 BL-8040
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by End User
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size
  • 2.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue 2014-2025
  • 2.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales 2014-2025
• 2.2 Relapsed Acute Myeloid Leukemia Drug Growth Rate by Regions
  • 2.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Regions
  • 2.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
  • 3.1.1 Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
  • 3.1.2 Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
  • 3.2.1 Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Relapsed Acute Myeloid Leukemia Drug Price by Manufacturers
• 3.4 Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Relapsed Acute Myeloid Leukemia Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Relapsed Acute Myeloid Leukemia Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Product
• 4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Product
• 4.3 Relapsed Acute Myeloid Leukemia Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Relapsed Acute Myeloid Leukemia Drug Breakdown Data by End User

6 North America

• 6.1 North America Relapsed Acute Myeloid Leukemia Drug by Countries
  • 6.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Countries
  • 6.1.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Relapsed Acute Myeloid Leukemia Drug by Product
• 6.3 North America Relapsed Acute Myeloid Leukemia Drug by End User

7 Europe

• 7.1 Europe Relapsed Acute Myeloid Leukemia Drug by Countries
  • 7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Countries
  • 7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Relapsed Acute Myeloid Leukemia Drug by Product
• 7.3 Europe Relapsed Acute Myeloid Leukemia Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug by Countries
  • 8.1.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Countries
  • 8.1.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug by Product
• 8.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug by End User

9 Central & South America

• 9.1 Central & South America Relapsed Acute Myeloid Leukemia Drug by Countries
  • 9.1.1 Central & South America Relapsed Acute Myeloid Leukemia Drug Sales by Countries
  • 9.1.2 Central & South America Relapsed Acute Myeloid Leukemia Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Relapsed Acute Myeloid Leukemia Drug by Product
• 9.3 Central & South America Relapsed Acute Myeloid Leukemia Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug by Countries
  • 10.1.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Countries
  • 10.1.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug by Product
• 10.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug by End User

11 Company Profiles

• 11.1 4SC AG
  • 11.1.1 4SC AG Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.1.5 4SC AG Recent Development
• 11.2 AbbVie Inc.
  • 11.2.1 AbbVie Inc. Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.2.5 AbbVie Inc. Recent Development
• 11.3 Actinium Pharmaceuticals, Inc.
  • 11.3.1 Actinium Pharmaceuticals, Inc. Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.3.5 Actinium Pharmaceuticals, Inc. Recent Development
• 11.4 Agios Pharmaceuticals, Inc.
  • 11.4.1 Agios Pharmaceuticals, Inc. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.4.5 Agios Pharmaceuticals, Inc. Recent Development
• 11.5 Amgen Inc.
  • 11.5.1 Amgen Inc. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.5.5 Amgen Inc. Recent Development
• 11.6 Arog Pharmaceuticals, Inc.
  • 11.6.1 Arog Pharmaceuticals, Inc. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.6.5 Arog Pharmaceuticals, Inc. Recent Development
• 11.7 Array BioPharma Inc.
  • 11.7.1 Array BioPharma Inc. Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.7.5 Array BioPharma Inc. Recent Development
• 11.8 Astellas Pharma Inc.
  • 11.8.1 Astellas Pharma Inc. Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.8.5 Astellas Pharma Inc. Recent Development
• 11.9 Astex Pharmaceuticals, Inc.
  • 11.9.1 Astex Pharmaceuticals, Inc. Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.9.5 Astex Pharmaceuticals, Inc. Recent Development
• 11.10 AstraZeneca Plc
  • 11.10.1 AstraZeneca Plc Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Products Offered
  • 11.10.5 AstraZeneca Plc Recent Development
• 11.11 AVEO Pharmaceuticals, Inc.
• 11.12 BioLineRx, Ltd.
• 11.13 Boehringer Ingelheim GmbH
• 11.14 Boston Biomedical, Inc.
• 11.15 Bristol-Myers Squibb Company
• 11.16 Calithera Biosciences, Inc.
• 11.17 Celgene Corporation
• 11.18 Cornerstone Pharmaceuticals, Inc.
• 11.19 CTI BioPharma Corp.

12 Future Forecast

• 12.1 Relapsed Acute Myeloid Leukemia Drug Market Forecast by Regions
  • 12.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Regions 2019-2025
• 12.2 Relapsed Acute Myeloid Leukemia Drug Market Forecast by Product
  • 12.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Product 2019-2025
• 12.3 Relapsed Acute Myeloid Leukemia Drug Market Forecast by End User
• 12.4 North America Relapsed Acute Myeloid Leukemia Drug Forecast
• 12.5 Europe Relapsed Acute Myeloid Leukemia Drug Forecast
• 12.6 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Forecast
• 12.7 Central & South America Relapsed Acute Myeloid Leukemia Drug Forecast
• 12.8 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Relapsed Acute Myeloid Leukemia Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details